Eurocine Vaccines AB Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
Sales 2022 | 0.07 0 | Sales 2023 | 0 0 | Capitalization | 9.09M 0 |
---|---|---|---|---|---|
Net income 2022 | -20M - | Net income 2023 | -18M - | EV / Sales 2022 | 119,226,800 x |
Net cash position 2022 | 14.24M 0 | Net cash position 2023 | 1.04M 0 | EV / Sales 2023 | 1,608,986,800 x |
P/E ratio 2022 |
-0.93
x | P/E ratio 2023 |
-0.41
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 4.17% |
Managers | Title | Age | Since |
---|---|---|---|
Hans Arwidsson
CEO | Chief Executive Officer | 66 | 03-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 86 | 11-12-31 | |
Hans Arwidsson
CEO | Chief Executive Officer | 66 | 03-12-31 |
Pär Thuresson
BRD | Director/Board Member | 64 | 03-12-31 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |